Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03875508 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 study of Psoriasis, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 108
- Enrollment target
- 20
- Study locations
NCT03875508 is a Phase 3 study of Psoriasis that has completed, run by AbbVie. The registered enrollment target is 108 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT03875508, a Phase 3 study of Psoriasis, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 108 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objectives of this study were to evaluate the usability of the combination product of risankizumab in an autoinjector (AI), as well as to evaluate the efficacy, safety, and tolerability of risankizumab administered by AI for the treatment of adult participants with moderate to severe plaque psoriasis.
Conditions Studied
Interventions
- DRUG Risankizumab
- DEVICE Autoinjector
Study Locations (20)
California
- Bakersfield Derma & Skin Cance /ID# 210773 - Bakersfield
- Encino Research Center / T. Jo /ID# 211735 - Encino
- Tien Q Nguyen MD, Inc /ID# 210775 - Fountain Valley
- UC Davis Health /ID# 210411 - Sacramento
Florida
- Florida Academic Centers Research /ID# 210337 - Coral Gables
- Medallion Clinical Research Institute, LLC /ID# 210329 - Naples
- Renstar Medical Research /ID# 210878 - Ocala
Arizona
- Advanced Research Associates /ID# 210634 - Glendale
- Cognitive Clinical Trials /ID# 210770 - Scottsdale
Michigan
- Great Lakes Research, Inc. /ID# 210192 - Bay City
- Somerset Skin Centre /ID# 211596 - Troy
Arkansas
- Burke Pharmaceutical Research /ID# 211386 - Hot Springs
Connecticut
- Dermatology Physicians of CT /ID# 210637 - Shelton
Kansas
- Epiphany Dermatology /ID# 211493 - Overland Park
Maryland
- DermAssociates /ID# 210838 - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2019-06-04 |
| Est. Completion | 2020-08-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03875508
The ClinicalTrials.gov registry entry for NCT03875508 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (78% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Risankizumab is the first listed.
NCT03875508 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT03875508 about?
NCT03875508 is a clinical study titled "A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis". The objectives of this study were to evaluate the usability of the combination product of risankizumab in an autoinjector (AI), as well as to evaluate the efficacy, safety, and tolerability of risankizumab administered by AI for the treatment of adult participants with moderate to severe plaque psor...
What is the current status of trial NCT03875508?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 108 participants. The study started on 2019-06-04. Estimated completion is 2020-08-25.
What conditions does trial NCT03875508 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT03875508?
The interventions under investigation include: Risankizumab (DRUG), Autoinjector (DEVICE).
Who is sponsoring clinical trial NCT03875508?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03875508 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.